ArticleDiabetologia2020
IGF-1 and cardiometabolic diseases: a Mendelian randomisation study.
Article in Diabetologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 78 citations in OpenAlex.
- Association between oxidative stress-related IGF-1 and prognosis after ischemic stroke: a systematic review and meta-analysis.Frontiers in neurology · 2025Pooled it
- New insights on the cardiovascular effects of IGF-1.Frontiers in endocrinology · 2023Pooled it
- IGF-1 and IGFBP-1 as Possible Predictors of Response to Lifestyle Intervention-Results from Randomized Controlled Trials.International journal of molecular sciences · 2024Trial
- The effect of SGLT2i on the GH/IGF1 axis in newly diagnosed male T2D patients - a prospective, randomized case-control study.Endocrine · 2024Trial
- Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial.Cardiovascular diabetology · 2023Trial
- Associations between Sugar-Sweetened Beverage Intake and Metabolic Syndrome among Postmenopausal Black Women with Obesity and a Family History of Breast Cancer.Cancer research communications · 2026Article
- Sex-specific roles of insulin-like growth factor-1, lean mass and fat mass in type 2 diabetes prevention: Mendelian randomization studies in Western and East Asian populations.Cardiovascular diabetology. Endocrinology reports · 2026Article
- The relationship between IGF-1 and cardiovascular diseases and the potential mediating role of TyG-related index: evidence from a cohort study.BMC cardiovascular disorders · 2026Article
- Insulin-like growth factor (IGF) and Insulin-like growth factor binding proteins (IGFBP) as predictors of type 2 diabetes risk in obese adults.Journal of diabetes and metabolic disorders · 2025Article
- Break free from cognitive impairment: The magic of exercise-induced molecules.Brain, behavior, & immunity - health · 2025Review
- Causal effects of primary aldosteronism on inflammation and bone density: evidence from Mendelian randomization, animal, and clinical studies.Diabetology & metabolic syndrome · 2025Article
- Article
- Immunological Markers of Cardiovascular Pathology in Older Patients.Biomedicines · 2025Article
- Plasma Insulin-like Growth Factor-Binding Protein-7 Is Positively Associated with Age, Obesity, Mortality, and Cancer in Postmenopausal Women.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Predictive value of growth hormone and insulin-like growth factor-1 axis for gestational diabetes mellitus: a prospective cohort study.BMC endocrine disorders · 2025Article
- Article
- Article
- An evolutionary medicine and life history perspective on aging and disease: Trade-offs, hyperfunction, and mismatch.Evolution, medicine, and public health · 2025Review
- Integrative Genetic Analysis of DPP4-Related Variants Reveals Risk Patterns for Type 2 Diabetes and Cardiometabolic Comorbidities.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
aims/hypothesisAbnormal serum IGF-1 levels are associated with an increased risk of type 2 diabetes and cardiovascular disease. However, the causal role of IGF-1 levels within the normal range in cardiometabolic disease remains unclear. We employed Mendelian randomisation to explore the associations between genetically predicted serum IGF-1 levels and cardiometabolic diseases.
methodsSerum IGF-1 levels were predicted using 416 SNPs associated with IGF-1 levels among 358,072 individuals in UK Biobank. Genetic association estimates for the outcomes were obtained from consortia of type 2 diabetes (74,124 cases, 824,006 controls), coronary artery disease (60,801 cases, 123,504 controls), heart failure (47,309 cases, 930,014 controls), atrial fibrillation (65,446 cases, 522,744 controls), and ischaemic stroke (60,341 cases, 454,450 controls).
resultsGenetic predisposition to elevated serum IGF-1 levels was associated with higher risk of type 2 diabetes and coronary artery disease. The OR (95% CI) per SD increment in IGF-1 level was 1.14 (1.05, 1.24) for type 2 diabetes and 1.09 (1.02, 1.16) for coronary artery disease. The association between IGF-1 and coronary artery disease was attenuated after adjustment for type 2 diabetes (OR 1.06 [95% CI 1.00, 1.13]), suggesting that the association may be partly mediated via type 2 diabetes. There was limited evidence of associations between IGF-1 levels and heart failure, atrial fibrillation and ischaemic stroke. CONCLUSIONS/
interpretationThis study found evidence that increased IGF-1 levels may be causally associated with higher risk of type 2 diabetes. Graphical abstract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.